Home

- Leukemia
  - Lymphocytic
    - Hairy cell leukemia
      - *▼10637: Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia
    - CD3+ acute lymphoma, or poor-risk chronic subtypes of adult t-cell lymphoma/leukemia
      - **10335:** A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
  - Myelogenous
    - R/R AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia
      - **10273:** A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia
      - **10434**: Randomized Phase 2 Study of CPX-351 + Pomalidomide versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes
      - **10237:** A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
      - **10538:** Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
      - ***10674:** A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    - AML with wild-type p53 (R/R or front line)
      - **10075:** A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia
      - ***10653:** A phase I study of Lintuzumab-Ac-225 in combination with venetoclax and ASTX-727 in adults with newly diagnosed AML
    - Mutated AML
      - **10596:** A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease
    - AML (front line therapy)
      - **10300:** BLAST MRD AML-1: A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
      - ***10674:** A phase I study evaluating the safety of Cirtuvivint as monotherapy and in combination with ASTX727 and ASTX727 + venetoclax in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)